Image by Pete Linforth from Pixabay.Angelini Ventures, the corporate venture capital arm of Angelini Industries, focused on investing in early-stage companies in BioTech and Digital Health, co-leads €20m Series A funding round in Neumirna Therapeutics, accelerating next-generation RNA therapeutics for epilepsy and neurological diseases.
Tag Archive for: Parkinson’s
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.